Search research articles
Contact Us
Filters
Showing results (51-60 of 112) with videos related to
Page
of 12
Sort By:
British Journal of Haematology
|
April 27, 2012
Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009
John A Snowden, Rachel M Pearce, Julia Lee, et al.
Plos One
|
September 27, 2016
Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia
Naeem Khan, Robert K Hills, Steve Knapper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2020
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses
Alan K Burnett, Nigel H Russell, Robert K Hills, et al.
Blood
|
April 3, 2015
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
Alan K Burnett, Nigel H Russell, Robert K Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2007
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Anna Sureda, Stephen Robinson, Carmen Canals, et al.
Blood
|
September 13, 2003
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
Rowena D Faulkner, Charles Craddock, Jennifer L Byrne, et al.
British Journal of Haematology
|
March 9, 2011
Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease
Bronwen E Shaw, Jane F Apperley, Nigel H Russell, et al.
Transplantation and Cellular Therapy
|
October 5, 2020
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
Siddhartha Ganguly, Jorge E Cortes, Alwin Krämer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2010
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy
Alan K Burnett, Nigel H Russell, Jonathan Kell, et al.
The Lancet. Oncology
|
September 19, 2015
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
Alan K Burnett, Nigel H Russell, Robert K Hills, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 112) with videos related to
Sort By:
Page
of 12
British Journal of Haematology
|
April 27, 2012
Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009
John A Snowden, Rachel M Pearce, Julia Lee, et al.
Plos One
|
September 27, 2016
Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia
Naeem Khan, Robert K Hills, Steve Knapper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2020
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses
Alan K Burnett, Nigel H Russell, Robert K Hills, et al.
Blood
|
April 3, 2015
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
Alan K Burnett, Nigel H Russell, Robert K Hills, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2007
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Anna Sureda, Stephen Robinson, Carmen Canals, et al.
Blood
|
September 13, 2003
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
Rowena D Faulkner, Charles Craddock, Jennifer L Byrne, et al.
British Journal of Haematology
|
March 9, 2011
Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease
Bronwen E Shaw, Jane F Apperley, Nigel H Russell, et al.
Transplantation and Cellular Therapy
|
October 5, 2020
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
Siddhartha Ganguly, Jorge E Cortes, Alwin Krämer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2010
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy
Alan K Burnett, Nigel H Russell, Jonathan Kell, et al.
The Lancet. Oncology
|
September 19, 2015
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
Alan K Burnett, Nigel H Russell, Robert K Hills, et al.
Page
of 12